JOURNAL BROWSE
Search
Advanced SearchSearch Tips
β-Adrenergic Receptors : New Target in Breast Cancer
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
β-Adrenergic Receptors : New Target in Breast Cancer
Wang, Ting; Li, Yu; Lu, Hai-Ling; Meng, Qing-Wei; Cai, Li; Chen, Xue-Song;
  PDF(new window)
 Abstract
Background: Preclinical studies have demonstrated that -adrenergic receptor antagonists could improve the prognosis of breast cancer. However, the conclusions of clinical and pharmacoepidemiological studies have been inconsistent. This review was conducted to re-assess the relationship between beta-adrenoceptor blockers and breast cancer prognosis. Materials and Methods: The literature was searched from PubMed, EMBASE and Web of Nature (Thompson Reuters) databases through using key terms, such as breast cancer and beta-adrenoceptor blockers. Results: Ten publications met the inclusion criteria. Six suggested that receiving beta-adrenoceptor blockers reduced the risk of breast cancer-specific mortality, and three of them had statistical significance (hazard ratio (HR)
 Keywords
Beta-adrenoceptor blockers;breast cancer;prognosis;systematic review;
 Language
English
 Cited by
1.
Metastasis Risk Reduction Related with Beta-Blocker Treatment in Mexican Women with Breast Cancer,;;;;;;;;

Asian Pacific Journal of Cancer Prevention, 2016. vol.17. 6, pp.2953-2957
 References
1.
World Health Organization (WHO) (2014): Breast cancer: prevention and control. Retrieved from .

2.
Akbar S1, Alsharidah MS (2014). Are beta blockers new potential anticancer agents? Asian Pac J Cancer Prev, 15, 9567-74. crossref(new window)

3.
Akechi T1, Okuyama T, Endo C, et al (2011). Patient's perceived need and psychological distress and/or quality of life in ambulatory breast cancer patients in Japan. Psychooncol, 20, 497-505. crossref(new window)

4.
Anil K. Sood, Guillermo N. Armaiz-Pena, et al (2010). Adrenergoc modulation of adhesion kinase protects human ovarian cells from anoikis. J Clin Invest, 120, 1515-23. crossref(new window)

5.
Antoni MH, Lutgendorf SK, Cole SW, et al (2006). The influence of bio-behavioural factors on tumour biology: Pathways and mechanisms. Nat Rev Cancer, 6, 240-8. crossref(new window)

6.
Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK (2009). Neuroendocrine modulation of cancer progression. Brain Behav Immun, 23, 10-5. crossref(new window)

7.
Avraham R, Benish M, Inbar S, et al (2010). Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression. Brain Behav Immun, 24, 952-8. crossref(new window)

8.
Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011). Beta blockers and breast cancer mortality: a population based study. J Clin Oncol, 29, 2635-44. crossref(new window)

9.
Barron TI, Sharp L, Visvanathan K (2012). Beta-adrenergic blocking drugs in breast cancer: a perspective review. Ther Adv Med Oncol, 4, 113-25. crossref(new window)

10.
Benish M, Bartal I, Goldfarb Y, et al (2008). Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol, 15, 2042-52. crossref(new window)

11.
Botteri E, Munzone E, Rotmensz N, et al (2013). Therapeutic effect of $\beta$-blockers in triple-negative breast cancerpostmenopausal women. Breast Cancer Res Treat, 140, 567-75. crossref(new window)

12.
Cakir Y, Plummer HK 3rd, Tithof PK, Schuller HM (2002). Betaadrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol, 21, 153-7.

13.
Cardwell CR, Coleman HG, Murray LJ, et al (2013). Betablocker usage and breast cancer survival: a nested casecontrol study within a UK clinical practice research datalink cohort. Int J Epidemiol, 42, 1852-61. crossref(new window)

14.
Carie AE, Sebti SM (2007). A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/ Mek-1/Erk1/2 pathway. Oncogene, 26, 3777-88. crossref(new window)

15.
Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S (2009). Catecholamines regulate tumor angiogenesis. Cancer Res, 69, 3727-30. crossref(new window)

16.
De Bruijn KM, Arends LR, Hansen BE, et al (2013). Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg, 100, 1421-9. crossref(new window)

17.
Diaz ES, Karlan BY, Li AJ (2012). Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol, 127, 375-8. crossref(new window)

18.
Drell TL 4th, Joseph J, Lang K, et al (2003). Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat, 80, 63-70. crossref(new window)

19.
Entschladen F, Drell TL 4th, Lang K, Joseph J, Zaenker KS (2004). Tumour-cell migration, invasion, and metastasis: Navigation by neurotransmitters. Lancet Oncol, 5, 254-8. crossref(new window)

20.
Fidler IJ (2003). The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer, 3, 453-8. crossref(new window)

21.
Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW (2011). Examining the Influence of Beta Blockers and ACE Inhibitors on the Risk for Breast Cancer Recurrence: Results from the LACE Cohort. Breast Cancer Res Treat, 129, 549-56. crossref(new window)

22.
Grytli HH, Fagerland MW, Fossa SD, Tasken KA, Haheim LL (2013). Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate, 73, 250-60. crossref(new window)

23.
Grytli HH, Fagerland MW, Fossa SD, Tasken KA (2014). Association between use of $\beta$-blockers and prostate cancerspecific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Uro, 65, 635-41. crossref(new window)

24.
Holmes MD, Hankinson SE, Feskanich D, Chen WY (2013). Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res Treat, 139, 507-13. crossref(new window)

25.
Holmes S, Griffith EJ, Musto G, Minuk GY (2013). Antihypertensive medications and survival in patients with cancer: A population-based retrospective cohort study. Cancer Epidemiol, 37, 881-5. crossref(new window)

26.
Huber JC1, Schneeberger C, Tempfer CB (2002). Genetic modelling of the estrogen metabolism as a risk factor of hormone-dependent disorders. Maturitas, 42, 1-12. crossref(new window)

27.
Landen CN Jr, Lin YG, Armaiz Pena GN, et al (2007). Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res, 67, 10389-96. crossref(new window)

28.
Lang K, Drell TL 4th, Lindecke A, et al (2004). Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer, 112, 231-8. crossref(new window)

29.
Liao S1, Li J, Wei W, Wang L, et al (2011). Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev, 12, 1061-5.

30.
Lutgendorf SK, Cole S, Costanzo E, et al (2003). Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res, 9, 4514-21.

31.
Madden, K.S., Szpunar, M.J. and Brown, E.B (2011). $\beta$-Adrenergic receptors ($\beta$-AR) regulate VEGF and IL-6 production by divergent pathways in high $\beta$-AR-expressing breast cancer cell lines. Breast Cancer Res Treat, 130, 747-58. crossref(new window)

32.
Masur K, Niggemann B, Zanker KS, Entschladen F (2001). Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res, 61, 2866-9.

33.
Melamed R, Rosenne E, Shakhar K, et al (2005). Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun, 19, 114-26. crossref(new window)

34.
Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al (2011). Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol, 29, 2645-52. crossref(new window)

35.
Ortiz-Mendoza CM, de-la-Fuente-Vera TA, Perez-Chavez E (2014). Metabolic syndrome in Mexican women survivors of breast cancer: a pilot study at a general hospital. Med Arch, 68, 19-21. crossref(new window)

36.
Palm D, Lang K, Niggemann B, et al (2006). The norepinephrinedriven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by betablockers. Int J Cancer, 118, 2744-9. crossref(new window)

37.
Park SY, Kang JH, Jeong KJ, et al (2011). Norepinephrine induces VEGF expression and angiogenesis by a hypoxiainducible factor-1 $\alpha$ protein-dependent mechanism. Int J Cancer, 128, 2306-16. crossref(new window)

38.
Perez Pinero C, Bruzzone A, Sarappa MG, Castillo LF, Luthy IA (2012). Involvement of $\alpha$2- and $\beta$2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. Br J Pharmacol, 166, 721-36. crossref(new window)

39.
Powe DG, Voss MJ, Zanker KS, et al (2010). Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget, 1, 628-38. crossref(new window)

40.
Powe DG, Voss MJ, Habashy HO, et al (2011). Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat, 130, 457-63. crossref(new window)

41.
Premal H. Thaker, Anil K. Sood (2008). The Neuroendocrine Impact of Chronic Stress on Cancer. Semin Cancer Biol, 18, 164-70. crossref(new window)

42.
Ronco AL1, De Stefani E, Deneo-Pellegrini H, Quarneti A (2012). Diabetes, overweight and risk of postmenopausal breast cancer: a case-control study in Uruguay. Asian Pac J Cancer Prev, 13, 139-46. crossref(new window)

43.
Sastry KS, Karpova Y, Prokopovich S, et al (2007). Epinephrine protects cancer cells from apoptosis via activation of cAMPdependent protein kinase and BAD phosphorylation. J Biol Chem, 282, 14094-100. crossref(new window)

44.
Shah SM, Carey IM, Owen CG, et al (2011). Dose $\beta$-adrenoceptor blocker therapy improve cancer survival? findings from a population-based retrospective cohort study. Br J Clin Pharmacol, 72, 157-61. crossref(new window)

45.
Shahzad MM, Arevalo JM, Armaiz-Pena GN, et al (2010). Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem, 285, 35462-70. crossref(new window)

46.
Shan T, Ma Q, Zhang D, et al (2011). $\beta$2-Adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Eur J Pharmacol, 665, 1-7. crossref(new window)

47.
Shi M, Liu D, Duan H, et al (2011). The $\beta$2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res Treat, 125, 351-62. crossref(new window)

48.
Sloan EK, Priceman SJ, Cox BF, et al (2010). The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res, 70, 7042-52. crossref(new window)

49.
Sood AK, Bhatty R, Kamat AA, et al (2006). Stress hormonemediated invasion of ovarian cancer cells. Clin Cancer Res, 12, 369-75. crossref(new window)

50.
Sood AK, Armaiz-Pena GN, Halder J, et al (2010). Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest, 120, 1515-23. crossref(new window)

51.
Susan K. Lutgendorf, Anil K. Sood, Michael H. Antoni (2010). Host factors and cancer progression: Biobehavioral signaling pathways and interventions. J Clin Oncol, 28, 4094-9. crossref(new window)

52.
Tang J1, Li Z, Lu L, Cho CH (2013). Seminars in Cancer Biology $\beta$-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol, 23, 533-42. crossref(new window)

53.
Thaker PH, Han LY, Kamat AA, et al (2006). Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med, 12, 939-44. crossref(new window)

54.
van Zitteren M1, van der Net JB, Kundu S, et al (2011). Genome-based prediction of breast cancer risk in the general population: a modeling study based on meta-analyses of genetic associations. Cancer Epidemiol Biomarkers Prev, 20, 9-22. crossref(new window)

55.
Werner H1, Bruchim I (2012). IGF-1 and BRCA1 signalling pathways in familial cancer. Lancet Oncol, 13, 537-44. crossref(new window)

56.
Xiao Y, Zhang S, Hou G, et al (2014). Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer. Tumour Biol, 35, 2035-45. crossref(new window)

57.
Yamazaki S, Miyoshi N, Kawabata K, et al (2014). Quercetin-3-O-glucuronide inhibits noradrenaline-promoted invasion of MDA-MB-231 human breast cancer cells by blocking $\beta$2-adrenergic signaling. Arch Biochem Biophys, 557, 18-27. crossref(new window)

58.
Yang EV, Bane CM, MacCallum RC, et al (2002). Stress-related modulation of matrix metalloproteinase expression. J Neuroimmunol, 133, 144-50. crossref(new window)

59.
Yang EV, Sood AK, Chen M, et al (2006). Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metal- loproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res, 66, 10357-64. crossref(new window)

60.
Ying Gao, Yu-Bei Huang, Xue-Ou Liu, et al (2013). Tea consumption, alcohol drinking and physical activity associations with breast cancer risk among chinese females: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 14, 7543-50. crossref(new window)

61.
Zhang D, Ma Q, Shen S, Hu H (2009). Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoeptor antagonist's anticancer effect in pancreatic cancer cell. Pancreas, 38, 94-100. crossref(new window)

62.
Zhang D, Ma QY, Hu HT, Zhang M (2010). Beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkB and AP-1. Cancer Biol Ther, 10, 19-29. crossref(new window)